Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed safety profile in Relapsed/Refractory Hodgkin Lymphoma patients
GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization
For people with relapsed or refractory diffuse large B-cell lymphoma
The acquisition further strengthens Torrent’s existing diabetes care portfolio and its presence in the Oral Anti Diabetic market
Aster DM Healthcare and Quality Care India Limited have signed definitive agreements to merge, subject to regulatory, corporate and shareholders’ approvals
The celebrations began with the unveiling of the Biocon Anthem
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xalatan
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality
Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR
Subscribe To Our Newsletter & Stay Updated
